Tsavaris N, Mylonakis N, Bacoyiannis C, Tsoutsos H, Karabelis A, Kosmidis P
Second Department of Medical Oncology, Metaxa Cancer Hospital, Piraeus, Greece.
Chemotherapy. 1993 Sep-Oct;39(5):361-6. doi: 10.1159/000239148.
Forty-one patients with advanced renal cell cancer started treatment with recombinant alpha-interferon intramuscularly, beginning at a dose of 5 x 10(6) U x 3/week, progressively increasing doses every week, from 5 x 10(6) U x 3/week to 10 x 10(6) U x 3/week, to the highest dose of 15 x 10(6) U x 3/week. No complete response was achieved, partial response was achieved in 6 (13%) patients with a median duration of 45.2 (13-134) weeks. The majority of side effects from interferon treatment evaluated according to WHO classification were seen during the first 2 months and they were fever (after interferon administration) in 95% patients, chills (51%), flu like syndrome (65%), fatigue (87%), anorexia (80%), worsening in performance status (56%), nausea and vomiting (19%), weight loss (> 10% during therapy) (26%), leukopenia (14%), anemia (75%), neurological symptoms (43%), psychological symptoms (19%) and dyspnea (9%). The results are similar to other studies and toxicity was only moderate.
41例晚期肾细胞癌患者开始接受重组α干扰素肌肉注射治疗，起始剂量为5×10⁶U×3/周，每周逐渐增加剂量，从5×10⁶U×3/周增至10×10⁶U×3/周，直至最高剂量15×10⁶U×3/周。未出现完全缓解，6例（13%）患者出现部分缓解，中位缓解持续时间为45.2（13 - 134）周。根据世界卫生组织分类评估，干扰素治疗的大多数副作用出现在前2个月，包括发热（注射干扰素后），95%的患者出现；寒战（51%）；流感样综合征（65%）；疲劳（87%）；厌食（80%）；体能状态恶化（56%）；恶心和呕吐（19%）；体重减轻（治疗期间>10%）（26%）；白细胞减少（14%）；贫血（75%）；神经症状（43%）；心理症状（19%）和呼吸困难（9%）。结果与其他研究相似，毒性仅为中度。
